Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
March 22, 2024Cancer Research

Abstract 4593: A synergy between MDM2 and AURKB pathways in driving cell cycle and cell survival in lung cancer cells

View Full Paper
Ask AI
Bookmark
Share

Authors

UNUmamaheswari NatarajanARAppu Rathinavelu

Discussion

Loading...

Member takes

Overview

In vitro study demonstrates dual MDM2 and AURKB pathway inhibition increases cell death in non-small cell lung cancer cells, suggesting cooperative targeting suppresses tumor survival.

Key Points

  • Combining the MDM2 inhibitor RG7388 with p38 or DNMT inhibitors increases cytotoxicity in non-small cell lung cancer cells, altering downstream survival factors.
  • In vitro experimental model analysis of A549 and H460 cells showed RG7388 promoted cell cycle arrest, elevating p53 levels while suppressing AURKB.
  • Dual targeting of MDM2 highlights cooperative cell death pathways in lung cancer; cell model observations indicate that further preclinical work is needed.

Cite This Study

Natarajan et al. (2024) studied this question.

synapsesocial.com/papers/68e72cd9b6db6435876a63b1https://doi.org/10.1158/1538-7445.am2024-4593
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5682: Micro RNA level changes in prostate cancer cells treated with MDMX and MDM2 inhibitors2024
  2. 2Abstract 5299: Epigenetic modulation by MDM2 and DNMT inhibitor promotes cell cycle arrest and programmed cell death in neuroblastoma cells2026
  3. 3Abstract 2865: Efficacy of MDM2 and epigenetic inhibitors treatments for neuroblastoma2024
  4. 4Abstract 4636: Deciphering radiation sensitivity identifies MDM2 as a targetable driver of synergistic radiosensitization in TP53 wild-type lung adenocarcinoma2026
  5. 5Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma2026